Partneringdesk deals and alliances in metabolic diseases

Summary

Reasons to purchase

Partneringdesk Deals and alliances in metabolic diseases provides a comprehensive summary of the deals and alliances announced in the field between January 2001 and March 2006, and helps in:

• the assessment of deal-making trends in the last five years
• identifying active partners
• tracking competitor activity
• benchmarking deals

Partneringdesk deals and alliances in metabolic diseases brings all the relevant partnering deals into one place, providing a ready reference to deal making in metabolic diseases.

Report scope

The report contains:

• fully categorized deal overviews
• financial information where disclosed
• company profiles of the top 25 dealmakers in the report
• specialized indexes by company, development stage, deal type and industry sector.
• wider coverage of Japanese deals courtesy of JCN

Description

Partneringdesk deals and alliances in metabolic diseases provides an in-depth view of over 670 deals and alliances announced in metabolic diseases between 2001 and 2006, in a clear and accessible PDF format.

Introduction

A diagrammatical and analytical summary of the deals and dealmakers in the therapy area over a five-year period.

Chapter 1: Deals by company

A comprehensive overview listing deals by company, with a full index of all the deals announced. A clear and easy way to see the activities of any company.

Chapter 2: Deals by development stage

A review of deals by stage of development. Appreciate how deal values change from discovery to launch in the therapy area.

Chapter 3: Deal type

Access deal information by type of transaction - see who is licensing or partnering and using what type of deal.

Chapter 4: Industry sector

Deal announcements sorted by industry sector. Choose from nine sectors.
Chapter 5: Top 25 company profiles
Summary profiles for the most active companies in the therapy area over the past five years, including contact details, business strategy, partnering strategy, R&D and history.

Chapter 6: Detailed listing of deals and alliances

A full index of all the deals announced between Jan 2001 and Mar 2006. Every deal entry includes a detailed deal description and financial information where disclosed, such as headline values, upfront and milestone payments.

Every deal entry includes a detailed deal description and financial information where disclosed, such as headline values, upfront and milestone payments, and links to the full deal in the deal listing at the rear of each report.

Who should buy the report

This report is essential reading for board and executive management, and individuals in:

• business development
• licensing/partnering
• deal making
• business strategy
• marketing and promotion
• distribution and manufacturing (including contract services).

Companies analyzed/mentioned

The report includes profiles from the following companies active in metabolic diseases:

• Abbott Laboratories
• American Diabetes Association (ADA)
• Amylin Pharmaceuticals Inc
• AstraZeneca
• Biovitrum AB
• Bristol-Myers Squibb Company
• Cholestech
• Eli Lilly and Company
• Entelos Inc
• GlaxoSmithKline
• HealtheTech Inc
• Illumina
• Kyorin Pharmaceutical
• Medical House plc, The
• Merck & Co Inc
• National Institutes of Health
• Novartis AG
• Novo Nordisk A/S
• Nutrition 21
• Pfizer Inc
• Roche
• Sankyo Co Ltd
• Sysmex Corporation
• Yamanouchi Pharmaceutical Co Ltd
• Zen-Bio

This report is derived from data obtained from Pharmalicensing's Partneringdesk deals and alliances database. The database is updated daily using industry sources.

Contents

• Introduction
• About Partneringdesk deals and alliances
• Chapter 1: Deals in metabolic diseases by company
• Chapter 2: Deals in metabolic diseases by development stage
• Chapter 3: Deals in metabolic diseases by type
• Chapter 4: Deals in metabolic diseases by industry sector
• Chapter 5: Summary profiles for the most active companies in metabolic diseases
• Chapter 6: List of deals
  • Glossary
• List of Figures:
  • Fig. 1 Deal activity 2001-2005
  • Fig. 2 Deal activity 2005
  • Fig. 3 Deal activity in metabolic diseases by year
  • Fig. 4 Deal activity in metabolic diseases by development stage (early stage)
  • Fig. 5 Deal activity in metabolic diseases by development stage (mid stage)
  • Fig. 6 Deal activity in metabolic diseases by development stage (late stage)
  • Fig. 7 Deal activity in metabolic diseases by type
  • Fig. 8 Deal activity in metabolic diseases by industry sector